Experience with dose escalation using CHARTWEL (continuous hyperfractionated accelerated radiotherapy weekend less) in non-small-cell lung cancer
Open Access
- 1 November 1998
- journal article
- clinical trial
- Published by Springer Nature in British Journal of Cancer
- Vol. 78 (10) , 1323-1328
- https://doi.org/10.1038/bjc.1998.678
Abstract
Results from the multicentre randomized trial of CHART (continuous, hyperfractionated, accelerated radiotherapy) in non-small-cell lung cancer (NSCLC) showed a significant increase in survival (P=0.004) compared with conventional radiotherapy and a therapeutic benefit relative to late radiation-induced morbidity. However, 60% of patients died because of failure to control locoregional disease. These findings have stimulated interest in assessing the feasibility of dose escalation using a modified CHART schedule. Acute and late morbidity with a CHARTWEL (CHART WeekEnd Less) schedule of 54 Gy in 16 days was compared with that observed with 60 Gy in 18 days in patients with locally advanced NSCLC. The incidence and severity of dysphagia and of analgesia were scored using a semiquantitative clinical scale. Late radiation-induced morbidity, namely pulmonary, spinal cord and oesophageal strictures, were monitored using clinical and/or radiological criteria. Acute dysphagia and the analgesia required to control the symptoms were more severe and lasted longer in patients treated with CHARTWEL 60 Gy (P< or = 0.02). However, at 12 weeks, oesophagitis was similar to that seen with 54 Gy and did not lead to consequential damage. Early radiation pneumonitis was not increased but, after 6 months, there was a higher incidence of mild pulmonary toxicity compared with CHARTWEL 54 Gy. No cases of radiation myelitis, oesophageal strictures or of grade 2 or 3 lung morbidity have been encountered. CHARTWEL 60 Gy resulted in an enhancement of oesophagitis and grade 1 lung toxicity compared with CHARTWEL 54 Gy. These were of no clinical significance, but may be important if CHARTWEL is used with concomitant chemotherapy. These results provide a basis for further dose escalation or the introduction of concurrent chemotherapy.Keywords
This publication has 13 references indexed in Scilit:
- Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trialThe Lancet, 1997
- The impact of overall treatment time on the results of radiotherapy for nonsmall cell lung carcinomaInternational Journal of Radiation Oncology*Biology*Physics, 1996
- A phase III study of accelerated radiotherapy with and without carboplatin in nonsmall cell lung cancer: An interim toxicity analysis of the first 100 patientsInternational Journal of Radiation Oncology*Biology*Physics, 1995
- Interruptions of high-dose radiation therapy decrease longterm survival of favorable patients with unresectable nonsmall cell carcinoma of the lung: analysis of 1244 cases from 3 radiation therapy oncology group (RTOG) trialsInternational Journal of Radiation Oncology*Biology*Physics, 1993
- The effect of increasing the treatment time beyond three weeks on the control of T2 and T3 laryngeal cancer using radiotherapyRadiotherapy and Oncology, 1992
- Assessment of Human Tumour Proliferation Using Bromodeoxyuridine—Current StatusActa Oncologica, 1991
- A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: report of Radiation Therapy Oncology Group 83-11.Journal of Clinical Oncology, 1990
- The recording of morbidity related to radiotherapyRadiotherapy and Oncology, 1989
- Primary tumor control after radiotherapy for carcinoma of the bronchusInternational Journal of Radiation Oncology*Biology*Physics, 1984
- A controlled clinical trial of misonidazole in the radiotherapy of patients with carcinoma of the bronchusInternational Journal of Radiation Oncology*Biology*Physics, 1982